Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 130

Results For "SEC"

3007 News Found

'Illness To Wellness’ joins hands with ILBS to generate awareness against Hepatitis B patients
News | March 23, 2024

'Illness To Wellness’ joins hands with ILBS to generate awareness against Hepatitis B patients

Hepatitis B infects over 40 million people in India


USFDA grants ODD to Cevidoplenib for immune thrombocytopenia
News | March 23, 2024

USFDA grants ODD to Cevidoplenib for immune thrombocytopenia

Oscotec has successfully completed phase 2 study in patients with chronic ITP last year


Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India
Drug Approval | March 23, 2024

Dr. Reddy's and Pharmazz inks agreement to market Centhaquine for hypovolemic shock in India

Centhaquine is a resuscitative agent presently indicated for the treatment of hypovolemic shock by DGCI


Merck invests € 300 million in new Life Science production site in South Korea
News | March 21, 2024

Merck invests € 300 million in new Life Science production site in South Korea

New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics


IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion
News | March 21, 2024

IFF to sell Pharma Solutions business to Roquette for US$ 2.85 billion

Pharma Solutions operates 10 research and development and/or production sites globally


Johnson Matthey sells Medical Device Components business for US$700 million to Montagu
Medical Device | March 21, 2024

Johnson Matthey sells Medical Device Components business for US$700 million to Montagu

The MDC business produces components for medical device manufacturers globally with a focus on precious metal alloys and nitinol


AstraZeneca buys biopharmaceutical company Fusion
News | March 20, 2024

AstraZeneca buys biopharmaceutical company Fusion

To accelerate the development of next-generation radioconjugates to treat cancer


Lonza to buy US biologics site from Roche for US$ 1.2 billion
Biotech | March 20, 2024

Lonza to buy US biologics site from Roche for US$ 1.2 billion

Lonza plans to invest approximately CHF 500 million to upgrade the facility


Syngene biologics facility to be operational for US, European customers from mid-year
News | March 17, 2024

Syngene biologics facility to be operational for US, European customers from mid-year

New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day